S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:ENOB

Enochian Biosciences Competitors

$3.54
-0.25 (-6.60 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.39
Now: $3.54
$3.78
50-Day Range
$3.02
MA: $3.63
$4.51
52-Week Range
$1.95
Now: $3.54
$13.43
Volume112,855 shs
Average Volume167,867 shs
Market Capitalization$169.08 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5

Competitors

Enochian Biosciences (NASDAQ:ENOB) Vs. CALT, ALBO, XENE, BCEL, CMRX, and KALV

Should you be buying ENOB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Enochian Biosciences, including Calliditas Therapeutics AB (publ) (CALT), Albireo Pharma (ALBO), Xenon Pharmaceuticals (XENE), Atreca (BCEL), Chimerix (CMRX), and KalVista Pharmaceuticals (KALV).

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Enochian Biosciences (NASDAQ:ENOB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares Calliditas Therapeutics AB (publ) and Enochian Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$19.56 million34.40$-3,450,000.00($0.19)-147.74
Enochian BiosciencesN/AN/A$-11,420,000.00N/AN/A

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Enochian Biosciences.

Institutional & Insider Ownership

11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 5.1% of Enochian Biosciences shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Calliditas Therapeutics AB (publ) and Enochian Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%
Enochian BiosciencesN/A-5.79%-5.47%

Analyst Ratings

This is a breakdown of recent ratings for Calliditas Therapeutics AB (publ) and Enochian Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Calliditas Therapeutics AB (publ)00503.00
Enochian Biosciences0000N/A

Calliditas Therapeutics AB (publ) currently has a consensus target price of $40.80, indicating a potential upside of 45.35%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, analysts plainly believe Calliditas Therapeutics AB (publ) is more favorable than Enochian Biosciences.

Summary

Calliditas Therapeutics AB (publ) beats Enochian Biosciences on 5 of the 8 factors compared between the two stocks.

Albireo Pharma (NASDAQ:ALBO) and Enochian Biosciences (NASDAQ:ENOB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares Albireo Pharma and Enochian Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Albireo Pharma-751.53%-71.22%-42.91%
Enochian BiosciencesN/A-5.79%-5.47%

Analyst Ratings

This is a breakdown of recent ratings for Albireo Pharma and Enochian Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Albireo Pharma00803.00
Enochian Biosciences0000N/A

Albireo Pharma currently has a consensus target price of $69.4286, indicating a potential upside of 99.16%. Given Albireo Pharma's higher probable upside, analysts plainly believe Albireo Pharma is more favorable than Enochian Biosciences.

Institutional & Insider Ownership

85.7% of Albireo Pharma shares are held by institutional investors. Comparatively, 5.1% of Enochian Biosciences shares are held by institutional investors. 5.0% of Albireo Pharma shares are held by insiders. Comparatively, 69.6% of Enochian Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Albireo Pharma and Enochian Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Albireo Pharma$9.64 million68.99$-62,720,000.00($5.04)-6.92
Enochian BiosciencesN/AN/A$-11,420,000.00N/AN/A

Enochian Biosciences has lower revenue, but higher earnings than Albireo Pharma.

Volatility and Risk

Albireo Pharma has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Enochian Biosciences has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

Enochian Biosciences (NASDAQ:ENOB) and Xenon Pharmaceuticals (NASDAQ:XENE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Enochian Biosciences and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enochian BiosciencesN/A-5.79%-5.47%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Analyst Ratings

This is a summary of current ratings and target prices for Enochian Biosciences and Xenon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enochian Biosciences0000N/A
Xenon Pharmaceuticals00603.00

Xenon Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 23.13%. Given Xenon Pharmaceuticals' higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Enochian Biosciences.

Insider and Institutional Ownership

5.1% of Enochian Biosciences shares are held by institutional investors. Comparatively, 79.9% of Xenon Pharmaceuticals shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by company insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Enochian Biosciences and Xenon Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enochian BiosciencesN/AN/A$-11,420,000.00N/AN/A
Xenon Pharmaceuticals$6.83 million95.74$-41,600,000.00($1.54)-12.13

Enochian Biosciences has higher earnings, but lower revenue than Xenon Pharmaceuticals.

Volatility & Risk

Enochian Biosciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Enochian Biosciences (NASDAQ:ENOB) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Enochian Biosciences and Atreca's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enochian BiosciencesN/A-5.79%-5.47%
AtrecaN/A-43.21%-40.98%

Analyst Ratings

This is a summary of current ratings and target prices for Enochian Biosciences and Atreca, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enochian Biosciences0000N/A
Atreca00603.00

Atreca has a consensus price target of $29.00, indicating a potential upside of 67.15%. Given Atreca's higher probable upside, analysts plainly believe Atreca is more favorable than Enochian Biosciences.

Insider and Institutional Ownership

5.1% of Enochian Biosciences shares are held by institutional investors. Comparatively, 69.6% of Atreca shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by company insiders. Comparatively, 9.9% of Atreca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Enochian Biosciences and Atreca's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enochian BiosciencesN/AN/A$-11,420,000.00N/AN/A
AtrecaN/AN/A$-67,480,000.00($4.26)-4.07

Volatility & Risk

Enochian Biosciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Atreca has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.

Summary

Enochian Biosciences beats Atreca on 5 of the 8 factors compared between the two stocks.

Enochian Biosciences (NASDAQ:ENOB) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Enochian Biosciences and Chimerix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enochian BiosciencesN/A-5.79%-5.47%
Chimerix-321.31%-36.57%-33.53%

Analyst Ratings

This is a summary of current ratings and target prices for Enochian Biosciences and Chimerix, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enochian Biosciences0000N/A
Chimerix00203.00

Chimerix has a consensus price target of $13.00, indicating a potential upside of 32.52%. Given Chimerix's higher probable upside, analysts plainly believe Chimerix is more favorable than Enochian Biosciences.

Insider and Institutional Ownership

5.1% of Enochian Biosciences shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by company insiders. Comparatively, 9.0% of Chimerix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Enochian Biosciences and Chimerix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enochian BiosciencesN/AN/A$-11,420,000.00N/AN/A
Chimerix$12.52 million49.08$-112,580,000.00($0.86)-11.41

Enochian Biosciences has higher earnings, but lower revenue than Chimerix.

Volatility & Risk

Enochian Biosciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Enochian Biosciences (NASDAQ:ENOB) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Volatility & Risk

Enochian Biosciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500.

Profitability

This table compares Enochian Biosciences and KalVista Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enochian BiosciencesN/A-5.79%-5.47%
KalVista Pharmaceuticals-229.45%-47.45%-41.84%

Earnings & Valuation

This table compares Enochian Biosciences and KalVista Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enochian BiosciencesN/AN/A$-11,420,000.00N/AN/A
KalVista Pharmaceuticals$12.69 million46.47$-29,120,000.00($1.64)-20.04

Enochian Biosciences has higher earnings, but lower revenue than KalVista Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for Enochian Biosciences and KalVista Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enochian Biosciences0000N/A
KalVista Pharmaceuticals00603.00

KalVista Pharmaceuticals has a consensus price target of $50.1667, indicating a potential upside of 52.62%. Given KalVista Pharmaceuticals' higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Enochian Biosciences.

Insider and Institutional Ownership

5.1% of Enochian Biosciences shares are held by institutional investors. Comparatively, 90.2% of KalVista Pharmaceuticals shares are held by institutional investors. 69.6% of Enochian Biosciences shares are held by company insiders. Comparatively, 18.0% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Enochian Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CALT
Calliditas Therapeutics AB (publ)
1.4$28.07-2.7%$672.81 million$19.56 million-20.19Analyst Report
News Coverage
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$34.86-0.6%$665.02 million$9.64 million-5.68Earnings Announcement
Analyst Revision
News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.4$18.68-3.0%$653.93 million$6.83 million-19.26Upcoming Earnings
Analyst Report
BCEL
Atreca
1.7$17.35-2.3%$636.87 millionN/A-6.15Earnings Announcement
News Coverage
Gap Down
Chimerix logo
CMRX
Chimerix
1.3$9.81-8.8%$614.44 million$12.52 million-17.21Earnings Announcement
News Coverage
Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$32.87-1.1%$589.75 million$12.69 million-15.80Analyst Report
Insider Selling
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$16.46-1.0%$589.50 millionN/A0.00Upcoming Earnings
Ardelyx logo
ARDX
Ardelyx
1.9$6.45-0.3%$582.10 million$5.28 million-6.39Upcoming Earnings
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.5$44.50-2.9%$579.84 million$195.89 million127.15Upcoming Earnings
Gap Down
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$12.17-12.2%$577.71 millionN/A-4.89Upcoming Earnings
Gap Down
IVA
Inventiva
0.0$15.00-3.6%$575.90 millionN/A0.00High Trading Volume
Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$6.77-3.0%$559.03 million$56.50 million0.00Gap Down
XBiotech logo
XBIT
XBiotech
1.2$19.00-0.3%$555.96 millionN/A1.32
Geron logo
GERN
Geron
1.4$1.79-1.1%$555.75 million$460,000.00-5.11
IDYA
IDEAYA Biosciences
1.3$19.07-4.7%$554.37 millionN/A-10.14Gap Up
APLT
Applied Therapeutics
1.8$21.72-5.6%$553.73 millionN/A-4.56Insider Buying
News Coverage
Gap Down
ISEE
IVERIC bio
1.5$6.14-2.1%$549.95 millionN/A-4.87Upcoming Earnings
News Coverage
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.90-1.1%$544.61 million$22.27 million-5.34Analyst Upgrade
Insider Buying
Gap Down
AC Immune logo
ACIU
AC Immune
1.3$7.59-0.9%$544.51 million$111.75 million-8.43
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$11.02-0.5%$543.45 million$72.96 million-3.57
RLMD
Relmada Therapeutics
1.1$33.34-1.5%$541.51 millionN/A-15.44Gap Down
BCYC
Bicycle Therapeutics
1.3$25.27-1.3%$538.38 million$13.80 million-12.21
UROV
Urovant Sciences
0.7$16.17-0.1%$529.45 millionN/A-3.14
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.99-0.8%$529.03 million$143.01 million-1.14Earnings Announcement
Analyst Report
Analyst Revision
ALT
Altimmune
1.9$15.94-7.9%$527.15 million$5.80 million-8.01Earnings Announcement
Analyst Revision
News Coverage
Gap Down
AMYT
Amryt Pharma
1.4$14.74-2.2%$527.10 million$58.12 million-17.14News Coverage
BeyondSpring logo
BYSI
BeyondSpring
1.2$12.98-0.6%$508.06 millionN/A-6.36News Coverage
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.51-1.5%$507.69 millionN/A-5.39Upcoming Earnings
News Coverage
Gap Up
NLTX
Neoleukin Therapeutics
1.4$12.04-3.2%$504.90 million$25 million-18.52News Coverage
Gap Down
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.6$15.29-1.6%$503.38 million$1.19 million-6.37
Affimed logo
AFMD
Affimed
1.6$5.67-5.3%$500.81 million$23.96 million-9.61News Coverage
Gap Up
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.43-5.0%$500.51 million$109.33 million-2.52News Coverage
Gap Down
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.6$3.46-0.3%$500.11 million$335 million-1.17Earnings Announcement
Analyst Revision
News Coverage
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.74-2.1%$499.66 millionN/A-13.76Analyst Upgrade
Analyst Revision
Gap Down
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$18.17-1.2%$493.99 million$18.15 million-4.28
SIGA
SIGA Technologies
0.3$6.32-0.9%$489.17 million$26.74 million15.80Upcoming Earnings
News Coverage
ETNB
89bio
1.6$24.56-1.3%$488.23 millionN/A-4.86
Homology Medicines logo
FIXX
Homology Medicines
1.7$10.74-0.9%$486.14 million$1.67 million-3.93High Trading Volume
SPRB
Spruce Biosciences
1.5$20.90-1.5%$485.17 millionN/A0.00Upcoming Earnings
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.26-4.6%$475.93 millionN/A-9.50Gap Up
MIRM
Mirum Pharmaceuticals
1.9$18.36-2.0%$472.16 millionN/A-5.34Analyst Upgrade
Gap Down
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$8.40-5.7%$472.06 million$1.98 million-5.06Upcoming Earnings
Analyst Upgrade
News Coverage
Gap Down
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.04-5.2%$468.52 million$59.22 million40.20Unusual Options Activity
News Coverage
Gap Down
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$20.00-4.5%$467.46 millionN/A0.00Upcoming Earnings
News Coverage
Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.11-0.1%$462.28 millionN/A-4.35
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$9.41-0.0%$459.00 million$15.98 million-1.66Upcoming Earnings
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.22-1.4%$455.89 million$6.68 million-5.08News Coverage
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.52-1.3%$455.64 million$49.65 million-2.14Upcoming Earnings
DURECT logo
DRRX
DURECT
1.4$2.22-1.8%$451.06 million$29.56 million-44.39Upcoming Earnings
BIVI
BioVie
1.7$32.10-9.8%$446.70 millionN/A0.00Gap Up
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.